Related references
Note: Only part of the references are listed.In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
Djordje Atanackovic et al.
LEUKEMIA (2020)
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mikhael et al.
BLOOD (2019)
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno et al.
CLINICAL CANCER RESEARCH (2019)
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma
Leo Rasche et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
Thomas Martin et al.
BLOOD CANCER JOURNAL (2019)
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
T. Facon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
Jean Kwun et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau et al.
LANCET (2019)
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition
Yilun Wu et al.
FRONTIERS IN IMMUNOLOGY (2019)
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Hartmut Goldschmidt et al.
ANNALS OF HEMATOLOGY (2019)
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Gilles Salles et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal et al.
LANCET (2019)
Immunotherapy in myeloma: how far have we come?
Laurens E. Franssen et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Paul G. Richardson et al.
FUTURE ONCOLOGY (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Global Burden of Multiple Myeloma ASystematic Analysis for the Global Burden of Disease Study 2016
Andrew J. Cowan et al.
JAMA ONCOLOGY (2018)
Phase I-b study of isatuximab plus carfilzomib in relapsed and refractory multiple myeloma (RRMM).
Ajai Chari et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W. C. J. van de Donk et al.
FRONTIERS IN IMMUNOLOGY (2018)
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
Hanley N. Abramson
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Fabio Morandi et al.
FRONTIERS IN IMMUNOLOGY (2018)
Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant
Enrique M. Ocio et al.
BLOOD (2018)
Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Meletios A. Dimopoulos et al.
BLOOD (2018)
Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone (D-Vd) Versus Bortezomib and Dexamethasone (Vd) in First Relapse Patients: Two-Year Update of Castor
Maria-Victoria Mateos et al.
BLOOD (2018)
A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics
Eric Robert Fedyk et al.
BLOOD (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies?
Francesco Zaja et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma.
J. Endell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma
Thomas Martin et al.
BLOOD (2017)
Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status.
Katja C. Weisel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis.
Limo Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunophenotype of Normal vs. Myeloma Plasma Cells: Toward Antibody Panel Specifications for MRD Detection in Multiple Myeloma
Juan Flores-Montero et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2016)
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
H. Jiang et al.
LEUKEMIA (2016)
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management
S. Vincent Rajkumar
AMERICAN JOURNAL OF HEMATOLOGY (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Multiple myeloma: patient outcomes in real-world practice
Kwee Yong et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2016)
Multiple Myeloma: Diagnosis and Treatment
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2016)
HLA-Incompatible Kidney Transplantation - Worth the Risk?
Lionel P. E. Rostaing et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices
Sundar Jagannath et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
Joshua Ryan Richter et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma
Thomas G. Martin et al.
BLOOD (2016)
Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells
Aneel Paulus et al.
BLOOD (2016)
Immunosurveillance and therapy of multiple myeloma are CD226 dependent (vol 125, pg 2077, 2015)
Camille Guillerey et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
B. Paiva et al.
LEUKEMIA (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients
S. Yousef et al.
BLOOD CANCER JOURNAL (2015)
NAD+-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model
Alberto L. Horenstein et al.
CELLS (2015)
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Inger S. Nijhof et al.
CLINICAL CANCER RESEARCH (2015)
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds
Rainer Boxhammer et al.
BLOOD (2015)
The generation of antibody-secreting plasma cells
Stephen L. Nutt et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Flow cytometry CD4+CD26-CD38+ lymphocyte subset in the microenvironment of Hodgkin lymphoma-affected lymph nodes
Rosa Di Gaetano et al.
ANNALS OF HEMATOLOGY (2014)
SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert et al.
CLINICAL CANCER RESEARCH (2014)
Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79
Jeroen Lammerts van Bueren et al.
BLOOD (2014)
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
H. Tamura et al.
LEUKEMIA (2013)
The state of therapy for removal of alloantibody producing plasma cells in transplantation
Matthew. J. Everly et al.
SEMINARS IN IMMUNOLOGY (2012)
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
A. Kalff et al.
BLOOD CANCER JOURNAL (2012)
The Activity of MOR202, a Fully Human Anti-CD38 Antibody, Is Complemented by ADCP and Is Synergistically Enhanced by Lenalidomide in Vitro and in Vivo
Jan Endell et al.
BLOOD (2012)
Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant Outcomes
M. Tonelli et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies
Neha Korde et al.
BLOOD (2011)
Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
Michael. S. van der Veer et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
M. S. van der Veer et al.
BLOOD CANCER JOURNAL (2011)
Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney Transplantation
Carmen Lefaucheur et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Bortezomib: a new player in pre- and post-transplant desensitization?
Anne Lemy et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology
Fabio Malavasi et al.
PHYSIOLOGICAL REVIEWS (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
CD38/CD19: a lipid raft-dependent signaling complex in human B cells
Silvia Deaglio et al.
BLOOD (2007)
Structure and enzymatic functions of human CD38
Hon Cheung Lee
MOLECULAR MEDICINE (2006)
Human CD38: a (r)evolutionary story of enzymes and receptors
S Deaglio et al.
LEUKEMIA RESEARCH (2001)
Share Paper
